| Authors: |
Spring LM; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Han H; Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL, USA., Liu MC; Mayo Clinic, Rochester, MN, USA., Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA., Irie H; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Santa-Maria CA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Reeves J; Florida Cancer Specialists-South/Sarah Cannon Research Institute, Fort Myers, FL, USA., Pan P; GSK, Waltham, MA, USA.; EQRx, Cambridge, MA, USA., Shan M; GSK, Waltham, MA, USA.; Translational Discovery & Development, Boston Pharmaceuticals, Boston, MA, USA., Tang Y; GSK, Waltham, MA, USA., Graham JR; GSK, Waltham, MA, USA.; Alkermes Incorporated, Waltham, MA, USA., Hazard S; GSK, Waltham, MA, USA.; Bicycle Therapeutics, Boston, MA, USA., Ellisen LW; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Isakoff SJ; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. SISAKOFF@mgh.harvard.edu. |
